Prothena Corporation plc Company Profile
NASDAQ: PRTAHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
Prothena at a glance
Prothena Corporation plc (NASDAQ: PRTA) is a Biotechnology: Pharmaceutical Preparations company in the Health Care sector headquartered in Dublin. Prothena is led by Dr. Gene G. Kinney Ph.D. and employs about 67 people. At a market capitalization of $422.1 million, it is considered a small-cap company.
Its SEC Central Index Key (CIK) is 0001559053, which identifies the company's filings on EDGAR.
Summary generated from market data by MetaCap's automated system. Methodology
What does Prothena do?
Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation. Its product pipeline includes Prasinezumab, an investigational humanized monoclonal antibody which is in Phase 3 clinical trial for the treatment of parkinson's disease and other synucleinopathies. The company also develops Coramitug, an investigational antibody, which is in Phase 3 clinical trial for the treatment of transthyretin amyloidosis; BMS-986446, an anti-tau antibody which is in Phase 2 clinical trial to treat Alzheimer's disease; PRX019, an investigational antibody which is in Phase 1 clinical trial for the treatment of neurodegenerative diseases; and PRX123, a Dual Aß-Tau Vaccine, which is in preclinical trial for treating Alzheimer's disease. In addition, it develops discovery- and late-preclinical-stage programs include TDP-43 CYTOPE for the treatment of amyotrophic lateral sclerosis; PRX012, a next-generation anti-Aß antibody which is in phase 1 clinical trial to treat Alzheimer's disease; and PRX012-TfR, a preclinical program for the treatment of Alzheimer's disease. It has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target a-synuclein, including prasinezumab; and master collaboration agreement with Bristol Myers Squibb to develop and commercialize antibodies targeting tau, TDP-43. Prothena Corporation plc was incorporated in 2012 and is based in Dublin, Ireland.
Business description based on the company's public filings.
Company information
- Legal name
- Prothena Corporation plc
- Ticker
- NASDAQ: PRTA
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Dr. Gene G. Kinney Ph.D.
- Employees
- 67
- Headquarters
- 77 Sir John Rogerson’s Quay, Dublin, United States
- Phone
- 353 1 236 2500
- Website
- prothena.com
- Market cap
- $422.10M
- SEC CIK
- 0001559053
Companies similar to Prothena
| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| ARVNArvinas Inc. | 6.46 | -4.15% | $423.03M | vs PRTA |
| CRMDCorMedix Inc. | 5.27 | +3.74% | $419.16M | vs PRTA |
| OVIDOvid Therapeutics Inc. | 2.20 | -5.98% | $415.21M | vs PRTA |
| EOLSEvolus Inc. | 6.52 | -6.86% | $431.55M | vs PRTA |
| INDPIndaptus Therapeutics Inc. | 2.82 | -9.90% | $433.16M | vs PRTA |
| AQSTAquestive Therapeutics Inc. | 3.46 | -6.61% | $434.88M | vs PRTA |
| CAPRCapricor Therapeutics Inc. | 7.59 | +0.80% | $441.30M | vs PRTA |
| LYELLyell Immunopharma Inc. | 13.80 | +1.62% | $441.82M | vs PRTA |